ABSTRACT-Addition of human cerebrospinal fluid (CSF) induced a marked inhibi tion of 3H-paroxetine binding to the monkey cortical membranes, while the specific binding of 3H-imipramine was slightly inhibited. Moreover, 3H-serotonin (5-hydroxy tryptamine, 5-HT) uptake inhibition in the monkey cortical synaptosomes was also in creased as the volume of added CSF was increased. Scatchard analysis of specific 3H paroxetine binding with human CSF showed non-competitive kinetics, although CSF was competitive with 3H-imipramine binding. The inhibitory effect of human CSF on 5-HT uptake was non-competitive in nature. The endogenous substances in human CSF most probably act at the recognition site labeled with 3H-paroxetine. Moreover, occupation of this site by the endogenous substances is likely to inhibit the 5-HT uptake process.
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High affinity binding sites for 3H-imipra mine have been demonstrated and character ized in membrane preparations from rat brain (1), the human platelets (2, 3) and human brain (4) . This recognition sites labeled with 3H -imipramine have been shown to be distinct but allosterically coupled with the serotonin (5-hydroxytryptamine, 5-HT) transport system (5-7). Several lines of evidence suggest that these sites are clinically important since a de crease in 3H-imipramine binding sites (8) as well as a decrease in 5-HT uptake (9) were re ported in platelets of depressed patients.
Recently, the existence of 3H-imipramine binding sites which regulate 5-HT uptake and the changes in presynaptic sites in imipramine binding and 5-HT uptake observed in depress ed patients suggest the possibility that these binding sites are regulated by unidentified en dogenous substance(s) in human plasma (10 12) or in rat brain and plasma (13, 14) . In addition, 5-methoxytryptoline has been dem onstrated as a potential endogenous modulator of 3H-imipramine binding and 5-HT uptake (15) . However, there is doubt about 5 methoxytryptoline's action as an endogenous ligand for the 3H-imipramine binding sites (16) . Other endogenous substances such as al acid glycoprotein (17) which are present in the low molecular weight fraction of human plas ma, inhibited 3H-imipramine binding, while enhancing 5-HT uptake.
Here we report the presence of and pre liminary characterization of a substance(s) in human cerebrospinal fluid (CSF) that inhibits 3H -5-HT uptake in monkey cortical synapto somal preparations and also inhibits 3H-imip ramine binding and 3H-paroxetine binding to monkey cortical membranes.
MATERIALS AND METHODS
The human cerebrospinal fluid (CSF) sam ples were obtained from normal subjects and patients in the course of routine diagnostic lumbar punctures. At this time, CSF samples picked from 10 individuals who were drug-free and had no familial history of psychiatric ill ness were collected in the Clinical Laboratory Center and used in the experiments after they were dialyzed in 0.001 M phosphate buffer (pH 7.4) overnight at 4°C to remove endoge nous monoamines and their metabolites, which would affect the studies. Monkeys were anesthetized with ketaral, given 30 mg/kg, s.c.; and their brains were quickly removed after withdrawing blood. The monkey brain and human CSF samples were stored at -30°C until use .
Receptor binding assay
The monkey cerebral cortex was homog enized in 25 vol. of ice-cold buffer (50 mM Tris HCl containing 100 mM NaCl and 5 mM KC1, pH 7.4). The P2 fractions obtained by centri fugation of this homogenate were used as the crude membrane preparations for the receptor binding assays. 3H-Imipramine binding to the monkey cortical membrane preparations (final concentration of approximately 0.1 mg protein/ ml) was performed according to the method of Kinnier et al. (18) . Desipramine at 10 MM fi nal concentration was used to determine non specific binding. 3H-Paroxetine binding to the monkey cortical membrane preparations (final concentration of approximately 0.1 mg protein/ml) using fluoxetine at 10,uM final concentration to assess the non-specific bind ing was performed according to the method of Habert et al. (19) . Aliquots of crude mem brane suspension were incubated with 3H-imip ramine at 0°C in the final volume of 250 ,ul for 60 min (for imipramine binding) or with 3H paroxetine at 22°C in the final volume of 250 ,ul for 180 min (for paroxetine binding). The incubation was terminated by rapid filtration of the membrane suspension under reduced pressure through Whatman GF/I fiber glass filters, and each filter was rapidly washed three times with 5 ml of ice-cold 50 mM Tris HCl buffer, pH 7.4. Then the filters were dried, and the radioactivities were determined in Triton X-100-toluene scintillation fluid in a liquid scintillation spectrometer. Specific bind ing represents the total binding minus binding in the presence of 10 M M desipramine or 10 ,uM fluoxetine, at imipramine or paroxetine concentrations ranging from 0.4 to 13.2 nM or 13 to 570 pM, in the absence and presence of the human CSF, respectively. Each Bmax and Kd was estimated by Scatchard analysis of the specific binding.
5-HT uptake
The uptake procedure of 3H-5-HT into synaptosomes was carried out by the method of Barbaccia et al. (10) . The monkey cerebral cortex was homogenized in 9 vol. of 0.32M sucrose, and the crude synaptosomal fractions were obtained by differential centrifugation. The crude synaptosomes were incubated for 2.0 min at 37°C in the absence and presence of 10 ,u M fluoxetine in the final volume of 500 ,u l with 3H-5-HT (to obtain final concentrations ranging between 50 to 750 nM) and Krebs bicarbonate buffer, pH 7.4. The incubation was terminated by rapid filtration of the sam ples under reduced pressure through GF/B glass fiber filters, and each filter was washed three times with 5 ml of ice-cold saline. Then the filters were dried, and the radioactivities present were counted by liquid scintillation spectrometry after adding Triton X-100 toluene scintillation fluid.
Protein determination
Protein concentrations were determined by the method of Lowry et al. (20) with bovine serum albumin as the standard. 
RESULTS
Inhibition of 3H-imipramine binding, 3H paroxetine binding to the monkey cerebral membranes and 3H-5-HT uptake in the mon key brain synaptosomes by human CSF As demonstrated in Fig. 1 , addition of a small aliquot of human CSF markedly inhib ited 3H-paroxetine binding. Under the assay conditions described, as little as 12 ,u l of CSF inhibited the 3H-paroxetine binding by 50%, and about 50,ul of CSF completely inhibited the binding.
When different volumes of human CSF (6 50 ,u l) were added to the incubation mixture containing 4 nM 3H-imipramine, the specific binding of 3H-imipramine slightly decreased as the volume of human CSF was increased.
The effects of the human CSF on 3H-5-HT uptake into the monkey cerebral synapto somes were studied. In these synaptosomal preparations, inhibition of 3H-5-HT uptake was increased as the volume of human CSF was increased.
Effect of the human CSF on the Bmax and Kd of 3H-paroxetine binding sites
The non-competitive nature of 3H paroxetine binding inhibition by the human CSF is demonstrated in Fig. 2 . Scatchard analysis of 3H-paroxetine binding to the monkey cortical membranes in the absence and presence of 25 ,u l of human CSF revealed an apparent decrease in both the Kd (0.63 ± 0.33 and 0.33 ± 0.27 nM in the absence and presence of the CSF, respectively) and Bmax (220 ± 71 and 109 ± 33 fmol/mg protein in the absence and presence of the CSF, respec tively), suggesting a non-competitive type of inhibition.
Effect of human CSF on the Bm and Kd of 3H -imipramine binding sites
The specific 3H-imipramine binding was assayed at different ligand concentrations (0.4 to 13.2 nM) in the presence and absence of 25 ,ul of human CSF, and the results were ana lyzed by Scatchard plots. Scatchard analysis of specific 3H-imipramine binding indicated a single population of binding sites with an apparent Kd of 4.52 ± 0.07 nM in the pres ence of CSF and 4.11 ± 0.01 nM, in the ab sence of CSF. Bmax was estimated to be 280 ± 111 fmol/mg in the presence of CSF and 305 ± 99 fmol/mg, in the absence of CSF. The antagonism by human CSF to 3H-imipramine binding was due to an increased Kd with no significant change in Bmax (Fig. 3) .
Lineweaver-Burk analysis of 3H-5HT uptake to the monkey cerebral synaptosomes in the ab sence and presence of human CSF Kinetic analysis of 3H-5-HT uptake into monkey cerebral synaptosomes and the effect of 25 ,u l of human CSF are shown in Fig. 4 . Using 3H-5-HT concentrations ranging from 50 to 750 nM, a single saturable high affinity uptake site was found. This transport process has an apparent Km of 400 ± 85 nM and a Vmax of 6.1 ± 0.5 pmol/min/mg protein. Figure 4 shows that the inhibitory effect of the human CSF was non-competitive in nature. 
DISCUSSION
The existence of 3H-imipramine binding sites in the brain and platelets of several spe cies including man has been demonstrated in a number of laboratories (3, 21) . The current evidence indicates that 3H-imipramine binding sites are located on serotonergic nerve termi nals and are closely associated with the 5-HT uptake system (21) . 3H-Imipramine binding sites are reduced following electrolytic lesions of the dorsal raphe and 5,7-dihydroxytrypta mine lesions (22, 23) , and the decrease in binding parallels the reduction in 5-HT uptake capacity (21) . Moreover, several authors have suggested that these sites are clinically impor tant, since a decrease in 3H-imipramine bind ing sites (8, 24, 25) as well as a decrease in 5 HT uptake (9) was reported in the platelets of depressed patients. These findings suggest that these binding sites are regulated by unidenti fied endogenous ligands.
Recently, several laboratories searched for endogenous 5-HT uptake modulators from rat brain (13) , rat plasma (14) or human plasma (10, 12) which inhibited 3H-imipramine bind ing or 5-HT uptake and suggested their pos sible roles in modulating serotonin uptake. Abraham et al. (17) also reported the evi dence of an endogenous modulator (like a, acid glycoprotein) in human plasma and sug gested that this modulator acts at the recogni tion site labeled by 3H-imipramine and acti vates the serotonin uptake process allosterical ly.
In this study, addition of a small aliquot of human CSF induced a marked inhibition of 3H -paroxetine binding , while the specific bind ing of 3H-imipramine slightly decreased as the volume of human CSF was increased. More over, 3H-5-HT uptake inhibition in monkey cortical synaptosomes also was linear with increasing human CSF volumes. Scatchard analysis of specific 3H-paroxetine binding in the presence of human CSF showed non-com petitive kinetics, while CSF was competitive with 3H-imipramine binding. In 5-HT uptake, the inhibitory effect of the human CSF was non-competitive in nature. These results indi cate that the endogenous substances in the human CSF inhibit preferentially paroxetine binding rather than imipramine binding. As far as we know, this is the first demonstration of the existence of the endogenous inhibitor like substances of the 5-HT uptake system in human CSF.
At present, the possible physiological sig nificance of the inhibitor-like substances in man is unknown. However, since preliminary experiments suggest a parallel inhibition of 3H -5-HT uptake and 3H-imipramine or paroxetine binding, the material(s) could rep resent the endogenous 5-HT uptake modula tor(s), and it may have a role in regulating serotonergic activity.
To support this view, however, the 5-HT uptake modulator(s) obtained from the human CSF requires further purification and more detailed testing for its inhibition of the 5-HT uptake system.
